Bicara Therapeutics (BCAX) Assets Average (2024 - 2026)

Bicara Therapeutics has reported Assets Average for 3 years, with the latest figure at $492.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average changed 0.35% year-over-year to $492.3 million; the trailing twelve-month figure through Mar 2026 stood at $492.3 million (changed 0.35% YoY), and the FY2025 full-year result was $470.5 million, up 26.48% from the prior year.
• Assets Average for Q1 2026 stood at $492.3 million, up from $427.8 million in the prior quarter.
• The five-year high for Assets Average was $517.1 million in Q4 2024, with the low at $427.8 million in Q4 2025.
• Historically, Assets Average has averaged $472.7 million across 3 years, with a median of $479.1 million in 2025.
• Annual changes were most pronounced in 2025 — Assets Average decreased 17.26% — and 2026, when it fell 0.35%.
• Bicara Therapeutics' Assets Average stood at $517.1 million in 2024, then fell by 17.26% to $427.8 million in 2025, then gained by 15.07% to $492.3 million in 2026.
• The last three Assets Average figures came in at $492.3 million (Q1 2026), $427.8 million (Q4 2025), and $439.1 million (Q3 2025), per Business Quant data.